NBRST PUBLICATIONS & ABSTRACTS

Clinical evidence from NBRST


Neoadjuvant publications

Evidence / Neoadjuvant / NBRST

ASCO 2020: Chemokine Signature

PUBLICATION: ASCO 20 AUTHORS: Hatem Soliman, Sangeetha Prabhakaran, Marilin Rosa, Charles Cox, Pat Whitworth, Sahra Uygun, Heather M. Kling, Erin B. Yoder, and William Audeh SUMMARY: Studies demonstrating the presence of immunoregulatory gene activation1 and tumor- infiltrating lymphocytes in the breast tumor microenvironment suggest the importance of an effective anti-tumor Read More

ASCO June 5 2019: Race and response to neoadjuvant chemotherapy

AUTHORS: Raquel Nunes, Femke de Snoo, Lisette Stork-Sloots, Tina Treece, Christa Dreezen, William Audeh DESCRIPTION: Race and response to neoadjuvant chemotherapy according to MammaPrint risk African-American (AA) women with breast cancer have a less favorable prognosis, likely due to differences in tumor biology. The Neoadjuvant BReast Cancer Symphony Trial (NBRST, Read More

Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers

PUBLICATION: npj Breast Cancer; volume 5, Article number: 15 (2019). AUTHORS: Floris H. Groenendijk, Tina Treece, Erin Yoder, Paul Baron, Peter Beitsch, William Audeh, Winand N. M. Dinjens, Rene Bernards & Pat Whitworth ABSTRACT: Immunohistochemically ER-positive HER2-negative (ER+HER2−) breast cancers are classified clinically as Luminal-type. We showed previously that molecular Read More

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

PUBLICATION: Ann Surg Oncol. 2017 Sep;24(9):2539-2546. doi: 10.1245/s10434-017-5863-x. AUTHORS:  Peter Beitsch, MD; Pat Whitworth, MD; Paul Baron, MD; Michael C. Rotkis, MD; Angela M. Mislowsky, MD; Paul D. Richards, MD; Mary K. Murray, MD; James V. Pellicane, MD; Carrie L. Dul, MD; Charles H. Nash, MD; Lisette Stork-Sloots, MSc; Femke Read More

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

PUBLICATION: Annals of Surgical Oncology; March 2017, Volume 24, Issue 3; pp 669–675. AUTHORS: Pat Whitworth, Peter Beitsch, Angela Mislowsky, James V. Pellicane, Charles Nash, Mary Murray, Laura A. Lee, Carrie L. Dul, Michael Rotkis, Paul Baron, Lisette Stork-Sloots, Femke A. de Snoo, Jennifer Beatty ABSTRACT: Hormone receptor-positive (HR+) tumors Read More

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

PUBLICATION: Ann Surg Oncol (2016) 23: 3317. https://doi.org/10.1245/s10434-016-5329-6. AUTHORS: Peter Beitsch, Pat Whitworth, Paul Baron, James Pellicane, Tina Treece, Erin Yoder, Mark Gittleman, NBRST Investigators Group SUMMARY: This substudy showed that NAT significantly altered the genomic signature of the patient's breast cancer compared with the patient's pre-treatment genomic profile. These Read More